白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
8期
472-474
,共3页
赵瑾%丰恺超%赵志强%苏丽萍%王军%马莉%贺建霞%王列样%李喜%王艳丽%韩维娥%郑玉萍
趙瑾%豐愷超%趙誌彊%囌麗萍%王軍%馬莉%賀建霞%王列樣%李喜%王豔麗%韓維娥%鄭玉萍
조근%봉개초%조지강%소려평%왕군%마리%하건하%왕렬양%리희%왕염려%한유아%정옥평
淋巴瘤,非霍奇金%抗肿瘤联合化疗方案%复发%难治
淋巴瘤,非霍奇金%抗腫瘤聯閤化療方案%複髮%難治
림파류,비곽기금%항종류연합화료방안%복발%난치
Lymphoma,non-Hodgkin%Antineoplastic combined chemotherapy protocols%Recurrence%Refractory
目的 研究GDP方案挽救治疗复发难治性非霍奇金淋巴瘤(NHL)的近期疗效及安全性.方法 回顾性分析接受GDP方案治疗的34例NHL患者的近期疗效及不良反应.GDP方案:吉西他滨1000 mg/m2静脉滴注,第1、8天,顺铂25 mg/m2静脉滴注,第1天至第3天,地塞米松40 mg/d静脉滴注,第1天至第4天,21d为1个周期,2个周期后评估疗效.结果 总有效率(ORR)为52.9％(18/34).复发性NHLORR为72.7％(8/11),难治性NHL为43.5％(10/23),二者比较差异无统计学意义(P=0.11);B-NHLORR为64.0％(16/25),T-NHL为22.2％(2/9),两组比较差异无统计学意义(P=0.052);低危组ORR为66.7％(6/9),中危组为55.6 ％(10/18),高危组为28.6％(2/7),低中危组的疗效优于高危组,但差异无统计学意义(P=0.349).Ⅲ～Ⅳ度粒细胞减少发生率为23.5％(8/34),无Ⅲ～Ⅳ度胃肠道不良反应及肝肾毒性.结论 GDP方案是复发难治性NHL的一种高效、低毒的二线挽救治疗方案.
目的 研究GDP方案輓救治療複髮難治性非霍奇金淋巴瘤(NHL)的近期療效及安全性.方法 迴顧性分析接受GDP方案治療的34例NHL患者的近期療效及不良反應.GDP方案:吉西他濱1000 mg/m2靜脈滴註,第1、8天,順鉑25 mg/m2靜脈滴註,第1天至第3天,地塞米鬆40 mg/d靜脈滴註,第1天至第4天,21d為1箇週期,2箇週期後評估療效.結果 總有效率(ORR)為52.9％(18/34).複髮性NHLORR為72.7％(8/11),難治性NHL為43.5％(10/23),二者比較差異無統計學意義(P=0.11);B-NHLORR為64.0％(16/25),T-NHL為22.2％(2/9),兩組比較差異無統計學意義(P=0.052);低危組ORR為66.7％(6/9),中危組為55.6 ％(10/18),高危組為28.6％(2/7),低中危組的療效優于高危組,但差異無統計學意義(P=0.349).Ⅲ～Ⅳ度粒細胞減少髮生率為23.5％(8/34),無Ⅲ～Ⅳ度胃腸道不良反應及肝腎毒性.結論 GDP方案是複髮難治性NHL的一種高效、低毒的二線輓救治療方案.
목적 연구GDP방안만구치료복발난치성비곽기금림파류(NHL)적근기료효급안전성.방법 회고성분석접수GDP방안치료적34례NHL환자적근기료효급불량반응.GDP방안:길서타빈1000 mg/m2정맥적주,제1、8천,순박25 mg/m2정맥적주,제1천지제3천,지새미송40 mg/d정맥적주,제1천지제4천,21d위1개주기,2개주기후평고료효.결과 총유효솔(ORR)위52.9％(18/34).복발성NHLORR위72.7％(8/11),난치성NHL위43.5％(10/23),이자비교차이무통계학의의(P=0.11);B-NHLORR위64.0％(16/25),T-NHL위22.2％(2/9),량조비교차이무통계학의의(P=0.052);저위조ORR위66.7％(6/9),중위조위55.6 ％(10/18),고위조위28.6％(2/7),저중위조적료효우우고위조,단차이무통계학의의(P=0.349).Ⅲ～Ⅳ도립세포감소발생솔위23.5％(8/34),무Ⅲ～Ⅳ도위장도불량반응급간신독성.결론 GDP방안시복발난치성NHL적일충고효、저독적이선만구치료방안.
Objective To study the effect and safety of GDP regimens (gemcitabine,cisplatin,dexamethasone) as salvage chemotherapy in relapsed refractory non-Hodgkin’s lymphoma (NHL).Methods Clinical response and adverse effects of 34 NHL patients treated by GDP regimens were analyzed retrospectively.Results The overall response rate (ORR) was 52.9 ％ (18/34),there was no statistic difference between ORR in relapsed NHL [72.7 ％ (8/11)] and that in refractory ones [43.5 ％ (10/23)](P =0.11).The ORR for B-NHL was 64.0 ％ (16/25),while for T-NHL was 22.2 ％ (2/9),there was no statistic difference between them (P =0.052).The ORR for low risks groups was 66.7 ％ (6/9),while it for intermediate-risk and high-risk ones were 55.6 ％ (10/18) and 28.6 ％ (2/7),respectively,the effect of GDP regimens for low-risk group was better for high-risk ones,but there was no statistic difference (P =0.349).The incedience of Ⅲ-Ⅳ granulopenia reduced was 23.5 ％ (8/34) and there were no Ⅲ-Ⅳ gastrointestinal adverse reactions or liver and kidney toxicity.Conclusion GDP regimens were efficient and less toxic as second-line salvage chemotherapy.
